Elias A. Zerhouni M.D.
About Elias A. Zerhouni M.D.
Elias A. Zerhouni M.D. President of OPKO Health
Elias A. Zerhouni M.D. currently holds the position of President at OPKO Health. In this role, he oversees the strategic direction and operational facets of the organization. In addition to his role as President, he serves as Vice Chairman, contributing to high-level decision-making processes essential for the company's growth and development in the healthcare sector.
Chairman and Co-founder of ModeX Therapeutics Inc.
Elias A. Zerhouni M.D. is the chairman and co-founder of ModeX Therapeutics Inc., a wholly-owned subsidiary of OPKO Health. ModeX Therapeutics focuses on delivering multispecific therapies designed to treat cancer and viral diseases. His leadership aims to drive innovative solutions in the field of oncology and infectious diseases, aligning with OPKO Health's mission to improve patient outcomes through advanced medical treatments.
Former President of Global R&D at Sanofi
From 2010 to 2018, Elias A. Zerhouni M.D. served as President of Global Research and Development (R&D) and Executive Vice President at Sanofi. In this capacity, he directed global research initiatives and development strategies, contributing substantially to Sanofi's advancements in pharmaceuticals and biotechnology. His tenure was marked by significant progress in drug development and innovation.
Leadership at the National Institutes of Health
Elias A. Zerhouni M.D. was the director of the U.S. National Institutes of Health (NIH) from 2002 to 2008. During his tenure, he played a pivotal role in enhancing the research capacity of the NIH, promoting innovative health research programs, and fostering collaborations across scientific disciplines. His leadership at the NIH was integral to advancing biomedical research and public health initiatives.
Awards and Recognitions
Throughout his career, Elias A. Zerhouni M.D. has received numerous accolades. In 2017, he was awarded the Scripps Executive of the Year Award for the pharmaceutical industry. Additionally, in 2008, he received the French Legion of Honor. His election to the National Academy of Medicine and the National Academy of Engineering further underscores his significant contributions to the fields of medicine and biomedical engineering.